Cspc Pharmaceutical

Cspc Pharmaceutical's reported carbon emissions

CSPC Pharmaceutical, a company in the Pharmaceutical Preparation Manufacturing industry with its headquarters in Hong Kong, has reported the following carbon emissions data. For the year 2024, CSPC Pharmaceutical's combined Scope 1 and Scope 2 emissions were approximately 967,877,000 kg CO2e. This comprised approximately 474,567,040 kg CO2e from Scope 1 and approximately 493,310,000 kg CO2e from Scope 2. In 2023, the company's Scope 1 and Scope 2 emissions totalled approximately 1,081,261,000 kg CO2e, with Scope 1 accounting for roughly 663,224,000 kg CO2e and Scope 2 for approximately 418,037,000 kg CO2e. Looking back to 2022, CSPC Pharmaceutical reported Scope 1 and Scope 2 emissions of approximately 1,137,042,000 kg CO2e, broken down into Scope 1 at approximately 564,429,000 kg CO2e and Scope 2 at about 572,613,000 kg CO2e. In 2021, Scope 1 and Scope 2 emissions were approximately 1,181,000,000 kg CO2e (Scope 1: 580,318,000 kg CO2e, Scope 2: 600,682,000 kg CO2e). For 2020, Scope 1 and Scope 2 emissions amounted to approximately 1,047,584,000 kg CO2e (Scope 1: 348,756,000 kg CO2e, Scope 2: 698,828,000 kg CO2e). Earlier reporting in 2019 indicated total emissions of approximately 1,124,435,000 kg CO2e, with Scope 1 at about 231,562,000 kg CO2e and Scope 2 at around 892,873,000 kg CO2e. In 2017, the company disclosed Scope 1, Scope 2, and Scope 3 emissions, totalling approximately 1,206,958,920 kg CO2e. This included Scope 1 at approximately 1,108,844,970 kg CO2e, Scope 2 at about 53,566,610 kg CO2e, and Scope 3 at approximately 44,547,340 kg CO2e. Note that Scope 3 emissions data is missing for the years 2019, 2020, 2021, 2022, 2023, and 2024. CSPC Pharmaceutical has established several reduction targets focused on emissions intensity. For greenhouse gas emissions per unit of revenue, the company aims to reduce emissions by 53% for the period 2024-2026 and by 60% for 2029-2030. Additionally, there is a target to reduce emissions by 56% for 2027-2028 for both Scope 1 and Scope 2 emissions per unit of revenue. These targets are measured against a 2017 baseline. The company also made a commitment in 2021 to reference the suggestions of the Task Force on Climate-related Financial Disclosures (TCFD) to identify climate-related risks and opportunities and to continuously improve its management system to minimise its carbon footprint from operational activities, with these commitments extending through 2025. CSPC Pharmaceutical Group Limited is the source of this emissions and initiative data, with no indication of data cascading from a parent organisation.